Sort
82,697 grants matching “vaccine development”
Epitope-targeted Vaccines for HIV-1 Prevention
$3,002,577Xiangpeng Kong · New York University School Of Medicine · P01 · FY2016 · AI
The Immunobiology of Marrow Allografts for Leukemia
$3,002,066Richard J O'Reilly · Sloan-Kettering Inst Can Research · P01 · FY2011 · CA
Structure-function analysis of infection- and vaccine-induced B-cell repertoires
$3,002,030Stephen C Harrison · Boston Children'S Hospital · P01 · FY2018 · AI
HIPC Data Coordinating Center
$3,001,925Bjoern Peters · La Jolla Institute For Immunology · U01 · FY2022 · AI
HIV/AIDS Vaccine and Antibody Development
$3,001,446Cheng Cheng · National Institute Of Allergy And Infectious Diseases · ZIC · FY2025 · AI
THERAPEUTIC INDEX OF ACUTE LYMPHOBLASTIC LEUKEMIA
$3,000,757Dana-Farber Cancer Institute · P01 · FY2001 · CA
Roles of protective or pathogenic B cell epitopes in human Lassa Fever
$3,000,694James Robinson · Tulane University Of Louisiana · N01 · FY2009 · AI
Unravelling immunoregulatory circuits of tissue inflammation
$3,000,357Behdad Afzali · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2021 · DK
Site Development for Emerging Diseases and Biodefense
$3,000,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2010 · AI
IP24-017 - Collaborative research on influenza and other respiratory pathogens in South Africa
$3,000,000Cheryl Cohen · National Health Laboratory Service · U01 · FY2024 · IP
ADVANCE CHIKUNGUNYA VACCINE CANDIDATES INTO LATER-PHASE CLINICAL TRIALS
$3,000,000Matt Westerman · Leidos Biomedical Research, Inc. · N01 · FY2015 · CA
Consortium for Viral Systems Biology (CViSB)
$3,000,000Kristian Graugaard Andersen · Scripps Research Institute, The · U19 · FY2018 · AI
Construction/SEBLAB/Regional Biocontainment Laboratory
$3,000,000Richard Banfield Marchase · University Of Alabama At Birmingham · UC6 · FY2006 · AI
Pandemic Infleuenza Virus Vaccines
$3,000,000Vaxin Inc. · UC1 · FY2005 · AI
Optimize VSA Adjuvants through Medicinal Chemistry Study
$3,000,000Adjuvax Llc · N44 · FY2025 · AI
DEVELOPMENT OF COVALENTLY BOUND HYALURONIC ACID AS AN ADJUVANT FOR MULTIVALENT LYME DISEASE VACCINE
$2,999,999Peter A Petillo · Design-Zyme, Llc · N44 · FY2024 · AI
US Influenza Vaccine Effectiveness Network
$2,999,990Arnold S Monto · University Of Michigan At Ann Arbor · U01 · FY2020 · IP
Improved Anthrax Vaccine Stability & use of Adjuvants
$2,999,760Allan Watkinson · Avecia Biologics, Ltd · UC1 · FY2007 · AI
VESIVAX TLR7 FORMULA
$2,999,352Samon Ho · Molecular Express, Inc. · N01 · FY2024 · AI
Treatment of Peanut Allergy with Intradermal Administration of ASP0892 (ARA-LAMP-vax): A Randomized, Double-Blind, Placebo-Controlled, Phase I/II Study
$2,998,654Robert A Wood · Johns Hopkins University · UM2 · FY2022 · AI
Immune Regulation In Toxoplasmosis And Other Opportunistic Infections
$2,998,583Alan Sher · Niaid Extramural Activities · Z01 · FY2007 · AI
Mechanisms and Duration of Immunity to SARS-CoV-2
$2,997,978Scott Dexter Boyd · Stanford University · U54 · FY2023 · CA
Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ Optimize Formulation of VSA Adjuvant
$2,997,218David Clements · Hawaii Biotech, Inc. · N44 · FY2022 · AI
Fast-Track Production of a Heptavalent Botulinum Vaccine
$2,997,064Dynport Vaccine Company, Llc · U01 · FY2005 · AI
Protective immunity following dengue virus natural infections and vaccination
$2,996,634Eva Harris · University Of California Berkeley · P01 · FY2016 · AI